| Old Articles: <Older 7451-7460 Newer> |
|---|
 |
The Motley Fool
May 17, 2011
Brian Orelli |
$3 Million Here, $1.5 Billion There Isis makes progress in its pact with GlaxoSmithKline.   |
The Motley Fool
May 17, 2011
Luke Timmerman |
Merck, Genentech Team Up on Hepatitis C Drug Merck pulling lots of strings to grab market share against Vertex. |
The Motley Fool
May 16, 2011
Brian Orelli |
Diabetes Drug Duo Duels It Out in Court Amylin sticks up to partner Eli Lilly. |
The Motley Fool
May 13, 2011
Karl Thiel |
Pacific Biosciences Has a PR Problem PacBio is hard to break down to a sound bite, but that could spell opportunity for long-term investors. |
The Motley Fool
May 13, 2011
Brian Orelli |
FDA Advisory Panel Positive! Shares Punished. Despite the positive recommendation, investors aren't convinced BioMimetic's Augment will be approved. |
BusinessWeek
May 12, 2011
David Armstrong |
Patients Sue Back Surgery Company Laser Spine The Laser Spine Institute draws flak over pricey surgeries. |
BusinessWeek
May 12, 2011
Robert Langreth |
Big Pharma Bets on a Novel Cancer Cure Research in epigenetics is booming. The payoff could be in the billions. |
The Motley Fool
May 12, 2011
Brian Orelli |
ViroPharma Gives It a Shot Testing a subcutaneous form of Cinryze. |
The Motley Fool
May 12, 2011
Brian Orelli |
Teva's Mixed Bag Diversification sure helps. |
The Motley Fool
May 12, 2011
Brian Orelli |
A Takeout Target Swims Along Amarin continues to develop AMR101. AMR101 recently passed two clinical trials: the first in patients with extremely high triglyceride levels, and a second in patients with moderate triglyceride levels. |
| <Older 7451-7460 Newer> Return to current articles. |
